Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early tirofiban after intravenous thrombolysis for disabling acute ischemic stroke
ChiCTR2400080653Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tirofiban in ischemic stroke (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Excellent functional outcome at 90 days, Symptomatic intracranial hemorrhage within 48 hours after tirofiban completion and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400080653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080653.